![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 47, 36869-36875, November 24, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Microbiology and Immunology, University of
California Los Angeles School of Medicine,
Los Angeles, California 90095
Received for publication, March 22, 2000, and in revised form, July 27, 2000
Pathogenic Yersinia species employ
type III machines to transport virulence factors across the bacterial
envelope. Some substrates for the type III machinery are secreted into
the extracellular medium, whereas others are targeted into the cytosol
of host cells. We found that during infection of tissue culture cells,
yersiniae secrete small amounts of LcrV into the extracellular medium.
Knockout mutations of lcrV abolish Yersinia
targeting and reduce expression of the lcrGVHyopBD operon.
In contrast, a block in LcrV secretion does not affect targeting, but
results in premature expression and secretion of Yop proteins into the
extracellular medium. LcrV-mediated activation of the type III pathway
is thought to occur by sequestration of the regulatory factor LcrG,
presumably via the formation of LcrV·LcrG complexes. These results
suggest that intrabacterial LcrV regulates the expression and targeting
of Yop proteins during Yersinia infection, whereas secreted
LcrV is required to ensure specificity of Yop injection into eukaryotic cells.
Pathogenic Yersinia species colonize the lymphoid
tissues of their infected hosts and require the type III machinery to
escape phagocytic killing by immune cells (1, 2). Bacterial entry into
the host triggers the synthesis and assembly of the type III machinery
(3-5). When exposed to high calcium concentrations within
extracellular fluids, the type III pathway of yersiniae is thought to
be inactive (6, 7). Bacterial attachment to host cells activates the
type III machinery, causing the secretion of YopBDR
(Yersinia outer
protein) into the extracellular medium (8-10) and the
targeting of YopEHMNOPT (effector Yop proteins) into the eukaryotic
cytosol (8, 11-16). The synthesis of effector Yop proteins is
regulated, and bacterial attachment to host cells results in a large
increase in yop gene expression (17). Once within the
eukaryotic cytosol, effector Yop proteins interfere with macrophage
signal transduction and actin polymerization (18-20), thereby
preventing bacterial phagocytosis and inducing the apoptotic demise of
immune cells (11, 16, 21).
The genes specifying type III machinery components, Yop proteins, as
well as regulatory factors are located on a 70-kilobase virulence plasmid (2). Loss of the virulence plasmid or of type III
machinery genes causes dramatic defects in the pathogenesis of
Yersinia infections (22). Bacterial growth at 37 °C and
the chelation of calcium from the culture medium artificially activate the Yersinia type III pathway, leading to the massive
secretion of 14 proteins (YopBDEHMNOPQRT, LcrV (low
calcium response), and YscM1/YscM2 (LcrQ)) into
the surrounding medium (yop) (23-25). Loss-of-function
mutations in any one of the 22 ysc (Yop
secretion) genes abrogate all protein export by
the type III pathway (26-29). Knockout mutations of lcrV do
not interfere with the secretion of Yop proteins under low calcium
conditions (30), but abolish the targeting of effector Yop proteins
into the cytosol of eukaryotic cells (31). In contrast, lcrG
mutant yersiniae secrete Yop proteins even in the presence of calcium,
suggesting that LcrG may regulate the expression or secretion of Yop
proteins (32-34). Straley and co-workers (35) observed LcrG binding to
LcrV in the bacterial cytoplasm and proposed a model whereby LcrG may
physically block the type III machinery. Binding to LcrV is thought to
interfere with the regulatory activity of LcrG, thereby activating the
type III pathway (titration model) (35). Recent observations suggest that LcrG functions as a chaperone, promoting type III secretion of
LcrV under conditions in which the secretion of effector Yop proteins
is blocked (5 mM
calcium).1
Using immunofluorescence microscopy, Wolf-Watz and co-workers (37)
observed LcrV staining on the surface of Yersinia
pseudotuberculosis. The addition of LcrV antiserum to tissue
culture cells prevents the type III injection of effector Yop proteins
(37). Straley and co-workers (31, 38) examined the fate of LcrV during
Yersinia pestis infection and reported that LcrV may be
surface-exposed as well as injected into the cytosol of HeLa cells.
These investigators observed no inhibition of type III targeting
following the addition of LcrV antiserum to infected tissue culture
cells (38). lcrV mutant yersiniae have been reported to be
defective in the type III secretion of YopB and YopD (30). Cornelis
(39) proposed a mechanism whereby the formation of an
LcrV·YopB·YopD complex allows type III export and assembly of an
injectisome on the bacterial surface. The Yersinia
injectisome, presumably composed of many proteins in addition to
LcrV·YopB·YopD, is thought to insert into the plasma
membrane of eukaryotic cells, thereby catalyzing the translocation of
effector Yop proteins (39). Nevertheless, the Yersinia
injectisome has not yet been purified or viewed by microscopy.
We have examined the subcellular location of LcrV during Yersinia
enterocolitica infection of HeLa cell cultures using the digitonin
fractionation technique (8). When incubated in tissue culture medium
with or without HeLa cells, yersiniae secrete YopBDR and LcrV into the
extracellular medium even in the presence of 1.8 mM
calcium. During infection of HeLa cultures, lcrV mutant yersiniae secrete YopBDR into the extracellular medium, but fail to
inject YopEHMN. This defect is complemented by plasmid-encoded wild-type lcrV and, at least in part, by
GST2-lcrV,
specifying a hybrid protein that cannot be exported by the type
III pathway. GST-LcrV copurifies with LcrG, but not with YopB or YopD.
Expression of GST-LcrV in lcrV mutant yersiniae causes the
same Los (loss of type III
targeting specificity) phenotype as knockout mutations of
lcrG, resulting in premature activation of the type III
targeting pathway and in secretion of all Yop proteins into the
extracellular medium. Thus, intrabacterial LcrV is essential for the
type III targeting pathway, whereas secreted LcrV appears to ensure the
fidelity of the Yop protein injection process.
Bacterial Strains and Plasmids--
Y. enterocolitica
strain W22703 (wild type) has been previously described (40). Y. enterocolitica strain CT1 (lcrV Yersinia Secretion--
Yersiniae were grown in tryptic soy
broth supplemented with 5 mM calcium chloride or 5 mM EGTA. Overnight cultures of Yersinia were
diluted 1:50 into 30 ml of fresh medium, grown for 2 h at 26 °C, and induced at 37 °C for 3 h. Cultures were
centrifuged at 10,500 × g for 15 min, and the
supernatant was separated from the cell pellet. Proteins in both
fractions were precipitated with trichloroacetic acid, washed with
acetone, and suspended in sample buffer. Proteins were analyzed by
SDS-PAGE and immunoblotting. Immunoreactive species were quantified as
chemiluminescent signals on x-ray film using laser densitometry scanning.
Yersinia Infection of HeLa Cell Cultures--
Overnight cultures
of Yersinia were diluted 1:20 into 30 ml of fresh Luria
broth and grown for 2 h at 26 °C with shaking. Bacteria were
sedimented at 8000 × g for 10 min and suspended in
phosphate-buffered saline. HeLa cells were grown to 80% confluency in
75-cm2 tissue culture flasks with Dulbecco's modified
Eagle's medium (DMEM) and 10% fetal bovine serum. Prior to infection,
cells were washed twice with PBS, covered with 10 ml of DMEM, and
warmed to 37 °C for 30 min. Aliquots of HeLa cells were counted, and each flask was infected with yersiniae at a multiplicity of infection of 10 and incubated for 3 h at 37 °C with 5% CO2.
The culture medium was removed and centrifuged at 32,000 × g for 15 min to separate soluble proteins from non-adherent
bacteria in the sediment. HeLa cells as well as adherent bacteria were
scraped off the flasks into 10 ml of digitonin in PBS and placed on a
rotary shaker for 20 min. Samples were centrifuged at 32,500 × g for 15 min. A 7-ml aliquot was withdrawn and precipitated
with chloroform/methanol, whereas the remaining supernatant was
discarded. The sediment was suspended in 10 ml of PBS, and a 7-ml
aliquot was precipitated with chloroform/methanol. Protein precipitates
were solubilized in sample buffer, separated on SDS-polyacrylamide gel,
and analyzed by immunoblotting with specific antiserum. Immunoreactive
species were quantified as chemiluminescent signals on x-ray film using laser densitometry scanning.
Purification of LcrV--
Escherichia coli
XL1-Blue/pVL1067 cells (1 liter) were grown to mid-log phase at
37 °C and induced with 1 mM
isopropyl-1-thio- Affinity Chromatography--
Overnight cultures of Y. enterocolitica CT1/pVL47 were diluted 1:50 into fresh tryptic soy
broth supplemented with 30 µg/ml chloramphenicol. Bacteria were grown
and induced by incubation for 2 h at 26 °C and for 3 h at
37 °C. Cells from 500 ml of culture were harvested by centrifugation
at 8000 × g for 15 min. The cell pellet was suspended
in 20 ml of buffer E (50 mM Tris-HCl, 20% sucrose, and 1 mM dithiothreitol, pH 7.0), and bacteria were broken by two
passages through a French pressure cell at 14,000 p.s.i. Unbroken cells
and debris were removed by centrifugation at 32,500 × g for 15 min. The supernatant, containing soluble
cytoplasmic extract, was subjected to affinity chromatography on
glutathione-Sepharose. The column was washed with 30 column volumes of
column buffer (50 mM Tris-HCl and 150 mM NaCl,
pH 7.5), and proteins were eluted with 4 ml of column buffer containing
10 mM glutathione. Eluted proteins were mixed with an equal
volume of sample buffer containing 3 M urea and analyzed by
SDS-PAGE and immunoblotting.
Microscopy--
HeLa cells were grown in DMEM and 10% fetal
bovine serum on glass coverslips in a 24-well plate for 48 h at
37 °C. Coverslips were washed with PBS and incubated with DMEM prior
to infection with Y. enterocolitica strains W22703/pDA37
(wild type, expressing plasmid-encoded Npt (neomycin
phosphotransferase)), CT1/pDA37 (lcrV Secretion of LcrV into the Extracellular Medium--
To determine
the fate of LcrV during infection, HeLa cell cultures were infected
with Y. enterocolitica W22703. The medium was decanted and
centrifuged, separating non-adherent bacteria from the extracellular
medium. HeLa cells and adherent yersiniae were extracted with
digitonin, thereby disrupting the cholesterol-containing plasma
membrane of eukaryotic cells. The bacteria were sedimented by
centrifugation and separated from the cytosol of HeLa cells. Proteins
in all fractions were precipitated with chloroform/methanol and
analyzed by immunoblotting (8). Digitonin extraction released p130Cas (45) from the cytosol of HeLa cells. Npt, a protein
residing in the Yersinia cytoplasm (46), was not released
and sedimented with the bacteria. The Yersinia type III
machinery secreted YopBDR into the extracellular medium and targeted
YopEH into the cytosol of HeLa cells. Small amounts of LcrV were found
in the extracellular medium; however, the majority of LcrV sedimented
with yersiniae after digitonin extraction of HeLa cells (Fig.
1A and Table
I). LcrV was not detected in the
supernatant of digitonin-extracted HeLa cells, suggesting that LcrV is
not injected into the cytosol of eukaryotic cells.
LcrV Secretion Occurs without Bacterial Attachment to HeLa
Cells--
To examine whether YopBDR and LcrV are secreted prior to
the attachment of yersiniae to eukaryotic cells, tissue culture medium (DMEM containing 0.2% fetal bovine serum and 1.8 mM
calcium) was inoculated with Y. enterocolitica W22703. After
incubation for 3 h, cultures were centrifuged, and the supernatant
and pellet fractions were precipitated with trichloroacetic acid and
analyzed by immunoblotting. YopBDR and LcrV were found in the tissue
culture medium, indicating that these proteins had been secreted even without bacterial attachment to HeLa cells (Fig. 1B and
Table I). YopE and YopH were not found in the tissue culture medium, but sedimented with the bacteria. This result is consistent with the
notion that export of type III targeting substrates requires bacterial
attachment to eukaryotic cells (11). As a control, Npt sedimented with
the bacteria into the pellet fraction.
LcrV Is Required for the Calcium Regulation of the lcrGVHyopBD
Operon--
A knockout mutation of lcrV was generated by
introducing a stop codon and +1 frameshift mutation at position 11 of
the lcrV open reading frame. To examine the role of LcrV in
type III secretion, Y. enterocolitica strains W22703 (wild
type) and CT1 (lcrV Intrabacterial LcrV Induces the lcrGVHyopBD Operon--
Fusion of
Yop proteins to the C terminus of glutathione S-transferase
abolishes their transport by the type III machinery (9). We wondered
whether the secretion of LcrV could also be blocked by fusion to GST.
Plasmid pVL47, encoding GST-LcrV, was transformed into Y. enterocolitica CT1. When expression of GST-LcrV was induced by the
addition of isopropyl-1-thio- Formation of Intracellular GST-LcrV·LcrG Complexes--
To
purify GST-LcrV from yersiniae, crude extracts of Y. enterocolitica CT1/pVL47 were centrifuged to remove cellular
debris. Soluble components of Yersinia cell extracts were
subjected to affinity chromatography on glutathione-Sepharose. Samples
were analyzed by Coomassie Blue-stained SDS-PAGE, revealing
copurification of GST-LcrV and LcrG (Fig.
3A). After immunoblotting,
immunoreactive signals in the eluate and load fraction were quantified,
and the eluate/load ratio was determined. Eluate/load ratios of 1.54 for LcrG and 1.93 for LcrV indicated enrichment of both polypeptides during affinity chromatography. These data confirmed previous observations that LcrV and LcrG form a complex in the cytosol of
yersiniae (35). Neither YopB nor YopD eluted with GST-LcrV, indicating
that these two polypeptides did not bind to LcrV. This was a surprising
result, as LcrV has been reported to interact with both YopB and YopD
(30). Failure of GST-LcrV to interact with YopB and YopD is likely not
caused by the fusion of GST, as purification of YopD from the cytoplasm
of yersiniae also did not yield copurified
LcrV.3
LcrV Is Required for the Type III Targeting of Effector Yop
Proteins--
To examine the role of LcrV in type III targeting, HeLa
cells were infected with Y. enterocolitica strains W22703
(wild type) and CT1 (lcrV Intrabacterial LcrV Complements the Targeting Defect of lcrV Mutant
Yersiniae--
Previous work suggested that LcrV may perform an
essential role for type III targeting (31, 37, 38). The observation that LcrV may be surface-displayed together with the result that anti-LcrV antibodies may block type III targeting suggested to us that the assembly of surface-exposed LcrV may be essential for the
injection of effector Yop proteins. If so, expression of GST-LcrV in
lcrV mutant yersiniae should not restore the targeting of
effector Yop proteins. To test this model, HeLa cells were infected
with Y. enterocolitica CT1/pVL47 and fractionated with the
digitonin technique (Fig. 5). As expected, GST-LcrV was not secreted
and localized to the bacterial sediment of the medium and
digitonin-extracted HeLa cells (Fig. 5). GST-LcrV induced the
expression of the yop virulon. Although large amounts of
YopBDEHMNQR were secreted into the extracellular medium, YopEHMN were
also found in the supernatant of digitonin-extracted HeLa cells (Fig. 5). Thus, GST-LcrV complemented, at least in part, the targeting defect
of lcrV mutant yersiniae, suggesting that intracellular LcrV, but not secreted or surface-exposed LcrV, is required for the
type III targeting mechanism.
To examine the type III targeting of HeLa cells by immunofluorescence
microscopy, infected tissue cultures were stained with anti-YopE
antibodies (Fig. 6). A YopE-specific
signal could be detected in the cytosol of HeLa cells that had been
infected with wild-type yersiniae. However, infection with the
lcrV mutant strain generated a much weaker YopE signal in
the cytosol of HeLa cells at a fluorescence intensity level resembling
the background level. As a control, HeLa cells that had been infected
with the yopE mutant LC2 or the lcrD mutant KUM1
(defective type III machine) also failed to generate a
fluorescent signal (data not shown). Y. enterocolitica CT1,
expressing LcrV (pVL49) or GST-LcrV (pVL47), generated a
YopE-specific immunofluorescent signal in the cytosol of HeLa cells,
indicating that LcrV as well as GST-LcrV restored the type III
targeting defect of lcrV mutant yersiniae (Fig. 6).
Our results suggest that expression of LcrV is essential for the
induction of the yop virulon and the targeting of effector Yop proteins during tissue culture infections. We wondered whether overexpression of GST-LcrV as well as LcrV in wild-type yersiniae leads
to sequestration of LcrG, thereby prematurely activating the type III
pathway. HeLa cells were infected with Y. enterocolitica strain W22703/pVL47 or W22703/pVL49 and analyzed by digitonin fractionation (Fig. 4). Constitutive expression of GST-LcrV and LcrV
from the tac promoter caused premature expression of the yop virulon and secretion of YopBDHMR into the extracellular
medium (Fig. 4). Nevertheless, type III targeting of yersiniae was not blocked, as YopEHMN were also found in the supernatant of
digitonin-extracted HeLa cells (Fig. 4). Thus, overexpression of
GST-LcrV or LcrV in a wild-type strain leads to up-regulation of the
Yersinia type III pathway, but does not cause the predicted
Los phenotype (massive secretion of YopEHMNQ), as observed for
lcrV mutant yersiniae expressing GST-LcrV. These results
suggest that secreted LcrV acts to ensure specificity of the targeting process.
Following host entry, pathogenic yersiniae are exposed to
37 °C, an environmental condition that triggers the expression of the transcriptional activator LcrF (VirF) and the assembly of the type
III machinery (47-49). Although high concentrations of calcium within
extracellular fluids prevent complete activation of the type III
pathway, we show here that yersiniae secrete YopBDR and LcrV into the
extracellular medium during the early stages of infection. YopD and
LcrV appear to fulfill a regulatory role (31, 50), and their secretion
could provide a measure for yersiniae that the type III machinery is
assembled and functional. YopB and YopR, on the other hand, are thought
to be dispensable for the regulation of type III pathways, but are
necessary for the establishment of acute disease in a mouse model
system (9). The role of these virulence factors during the pathogenesis
of Yersinia infections has thus far not been characterized.
Attachment of yersiniae to host cells appears to transform the type III
pathway into an injection device that promotes the type III targeting of YopEHMNOPT into the eukaryotic cytosol.
Intrabacterial LcrV is absolutely required for type III targeting to
occur. This requirement could be due to the LcrV·LcrG-mediated regulation of the lcrGVHyopBD operon, encoding another
factor (YopD) that is required for type III targeting (9, 11, 14). Although the molecular details of regulation are not known, we would
like to entertain two possibilities of altering the ratio between LcrV
and LcrG in bacteria. Attachment of yersiniae to host cells may trigger
increased expression of LcrV, and the burst of LcrV synthesis could
sequester LcrG molecules. As lcrG and lcrV are
transcribed from the same promoter, any burst of LcrV expression would
have to be regulated at a level of post-transcriptional control. The
second model predicts that attachment of yersiniae to eukaryotic cells
results in a block of LcrV secretion, raising the intracellular LcrV
concentration and sequestering LcrG molecules. Currently, available
data do not permit a clear distinction between the two models. It
should be noted, however, that even small changes in the intracellular
concentration of LcrV could exert a regulatory effect, as they would be
accompanied by reciprocal changes of the regulatory molecule LcrG.
Secretion of LcrV during tissue culture infection of yersiniae
ensures the specificity of Yop protein injection into eukaryotic cells.
We cannot exclude the possibility that LcrV may play a role in the
formation of a type III injection device (30, 37). Using
immunofluorescence microscopy, discrete patterns of LcrV staining have
been revealed on the Yersinia surface (37, 38). Whether this
staining is caused by the assembly of LcrV filaments or by the
secretion of LcrV into the surrounding medium is not yet resolved (37,
38). In other work, we have found that Y. enterocolitica
cells harbor intracellular, soluble LcrV·LcrG complexes, but no
membrane-associated LcrV.1 These data are not consistent
with a model whereby LcrV forms a structure that assembles on the
Yersinia outer membrane surface. The role of surface-exposed
LcrV in the type III targeting mechanism has been examined by several
investigators. Some, but not all, experiments suggest that antibodies
raised against purified LcrV can block the type III targeting mechanism
(37, 38). Nevertheless, LcrV antiserum is known to protect animals
against an experimental challenge of Y. pestis (51-54).
When injected into mice, purified LcrV reduces tumor necrosis
factor- Recent observations suggest that LcrG fulfills two
functions.1 Binding of LcrG to the C-terminal domain of
LcrV initiates LcrV into the type III secretion pathway.1
Furthermore, LcrG is required to prevent expression of the
yop virulon under non-inducing conditions (34).1
We think the inability of lcrG mutant yersiniae to secrete
LcrV likely causes the observed Los phenotype of this
strain.1 Consistent with this model is our observation that
lcrV mutant yersiniae overexpressing GST-LcrV display the
same Los phenotype as the lcrG mutant strain. In contrast,
wild-type yersiniae expressing GST-LcrV maintain at least some
specificity of injection (YopEN), presumably because this strain is
still capable of secreting wild-type LcrV.
We thank members of our laboratory for
critical comments on this manuscript.
*
This work was supported in part by United States Public
Health Service Grant AI 42797.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Dept. of Microbiology
and Immunology, UCLA School of Medicine, 10833 Le Conte Ave., Los
Angeles, CA 90095. Tel.: 310-206-0997; Fax: 310-267-0173; E-mail:
olafs@ucla.edu.
Published, JBC Papers in Press, August 4, 2000, DOI 10.1074/jbc.M002467200
1
K. DeBord, V. T. Lee, M. Chu, and O. Schneewind, submitted for publication.
3
D. M. Anderson and O. Schneewind,
unpublished data.
The abbreviations used are:
GST, glutathione
S-transferase;
PCR, polymerase chain reaction;
PAGE, polyacrylamide gel electrophoresis;
DMEM, Dulbecco's modified Eagle's
medium;
PBS, phosphate-buffered saline.
LcrV, a Substrate for Yersinia enterocolitica Type
III Secretion, Is Required for Toxin Targeting into the Cytosol of
HeLa Cells*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
) was
constructed by allelic exchange using the suicide plasmid pLC28 (41).
The lcrV1 allele was designed as a mutation that introduced
a stop codon at position 11 of the lcrV open reading frame
(42, 43), followed by a +1 reading frameshift and a unique
EcoRI site as a fusion joint between two DNA fragments. lcrV1 was constructed from two PCR products that were
amplified using primers LcrV.1 (5'-AAGAGCTCACCAGTGCAGGGAGTTATTT-3') and LcrV.2 (5'-AAGAATTCACTATTGTGGGTTTTGTTCGTAGGC-3') as well as primers LcrV.3 (5'-AAGAATTCACATTTATTGAGGATCTAGAAAA-3') and LcrV.4
(5'-AACTGCAGTGAGTGTCTGTCGTCTCTTG-3'). The PCR products were cut with
SacI-EcoRI or EcoRI-PstI,
fused at the EcoRI site, and cloned between the
SacI-PstI sites of pLC28. To generate pVL49, the
lcrV open reading frame was PCR-amplified with two primers
carrying abutted NdeI and BamHI restriction
sites: LcrV.5 (5'-AACATATGATTAGAGCCTACGAACAA-3') and LcrV.6
(5'-AAGGATCCTCATTTACCAGACGTGTCATC-3'). The PCR product was digested
with NdeI-BamHI and cloned between the
NdeI and BamHI sites of the low-copy-number
plasmid pVL41 (9) to generate pVL49. pVL47 was generated by PCR
amplification using primers LcrV.6 and LcrV.7
(5'-AAGGTACCATTAGAGCCTACGAACAAAACC-3'). lcrV sequences were
cut with KpnI-BamHI and cloned into pDA255 (44).
Expression of LcrV and GST-LcrV is under the control of the
tac promoter. The lacIQ allele is also
cloned on the low-copy-number vector, and Y. enterocolitica transformants were induced for expression of LcrV and GST-LcrV by the
addition of 1 mM
isopropyl-1-thio-
-D-galactopyranoside. To raise
LcrV-specific antibody, the N-terminal domain of LcrV was appended to
an affinity tag and purified. lcrV coding sequence was
PCR-amplified with primers that carry abutted BamHI sites (LcrV.8, 5'-AAGGATCCATGGCTTACGACCTTTCTGAG-3'; and LcrV.9,
5'-AAGGATCCAATTTTTAATTCGGCGGTAAGC-3'). The PCR product was digested
with BamHI and cloned into pQE30 (QIAGEN Inc.), thereby
generating pVL1067.
-D-galactopyranoside for 3 h.
Cells were harvested by centrifugation at 8000 × g for 15 min and suspended in 20 ml of buffer A (6 M guanidine
hydrochloride, 0.1 M NaH2PO4, and
0.01 M Tris-HCl, pH 8.0). The sample was incubated with
intermittent vortexing on ice for 1 h. Insoluble material was
removed by centrifugation at 32,000 × g for 10 min.
The supernatant was loaded onto a 1-ml column of
nickel-nitrilotriacetic acid-Sepharose that had been pre-equilibrated
with 10 ml of buffer A. The column was washed with 10 ml of buffer A,
10 ml of buffer B (8 M urea, 0.1 M
NaH2PO4, and 0.01 M Tris-HCl, pH
8.0), and 20 ml of buffer C (same as buffer B, but pH 6.3).
LcrV-His6 was eluted with 4 ml of buffer D (same as buffer
B, but pH 4.5). Samples were aliquoted and stored frozen at
80 °C.
Purified LcrV was emulsified with Freund's adjuvant and injected into
rabbits to raise polyclonal antibodies. Antiserum reactivity and
specificity were examined by comparing bacterial extracts of wild-type
and mutant lcrV strains with the purified antigen.
, expressing plasmid-encoded Npt),
CT1/pVL49 (expressing plasmid-encoded wild-type LcrV), and
CT1/pVL47 (expressing plasmid-encoded GST-LcrV) for 3 h at
an multiplicity of infection of 20. After infection, coverslips were
fixed with 3.7% formaldehyde for 10 min. All fixation was quenched by
adding 0.1 M glycine for 10 min, followed by
permeabilization with 0.1% Triton X-100 for 10 min. Samples were
blocked with 3% bovine serum albumin in PBS for 30 min. Coverslips
were then incubated with anti-YopE polyclonal antibodies for 45 min.
After washings with PBS, samples were incubated with fluorescein
isothiocyanate-conjugated anti-rabbit IgG antibody (Jackson
ImmunoResearch Laboratories, Inc.) for 45 min. Samples were washed and
viewed under a fluorescence microscope. Images were captured with a
Hamamatsu CCD camera.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (53K):
[in a new window]
Fig. 1.
Yersiniae secrete YopBDR
and LcrV into the extracellular medium. A, infection of
HeLa cells with Y. enterocolitica W22703. HeLa cells were
infected for 3 h. The tissue culture medium (Med) was
decanted and centrifuged to separate secreted proteins (supernatant
(S)) from those present within non-adherent bacteria (pellet
(P)). HeLa cells and adherent yersiniae were extracted with
digitonin (Dig), a detergent that solubilizes the eukaryotic
plasma membrane, but not the bacterial envelope. Extracts were
centrifuged to separate proteins solubilized from the HeLa cytoplasm
(supernatant) from those that sedimented with the bacteria (pellet).
Proteins in each fraction were precipitated with chloroform/methanol
and analyzed by SDS-PAGE and immunoblotting. p130Cas is
located in the cytoplasm of HeLa cells, whereas Npt is located in the
cytoplasm of yersiniae. Y. enterocolitica W22703 injected
YopE and YopH into HeLa cells, whereas YopBD and LcrV were secreted
into the extracellular medium. B, Y. enterocolitica W22703 was incubated in tissue culture medium (DMEM
with 0.2% fetal bovine serum and 1.8 mM calcium) and
incubated for 3 h at 37 °C. Cultures were centrifuged to
separate proteins secreted into the extracellular medium with the
supernatant from those that sedimented into the bacterial pellet.
Samples were precipitated with trichloroacetic acid and analyzed by
SDS-PAGE and immunoblotting. In the presence of 1.8 mM
calcium, yersiniae secreted YopBDR and LcrV into the extracellular
medium, whereas YopEH and Npt were not secreted. See Table I for
quantification of the data.
Yersinia type III secretion with and without HeLa tissue culture cells
) were grown at 37 °C in
the presence or absence of 5 mM calcium. Cultures were
centrifuged, and the supernatant and pellet fractions were precipitated
with trichloroacetic acid and analyzed by immunoblotting (Fig.
2). When induced by low calcium,
wild-type yersiniae secreted YopBDE and LcrV into the extracellular
medium. As a control, LcrG and LcrH, two bacterial chaperones, were
found in the sediment of all cultures examined. The addition of calcium
reduced the expression and type III secretion of YopBDE. In contrast,
LcrV was found secreted equally in the presence and absence of calcium. The lcrV mutant strain CT1 expressed less LcrGH and YopBD
than did wild-type yersiniae both in the presence and absence of
calcium (Table II). Nevertheless,
in the absence of calcium, YopBD were secreted at a level
similar to that observed for the wild-type strain. Transformation of
Y. enterocolitica CT1 with pVL49, encoding wild-type
lcrV, not only restored LcrV expression and secretion, but
also increased the expression of the lcrGVHyopBD operon
(Table II). The data suggest that lcrV knockout mutations
result in reduced expression of the lcrGVHyopBD operon
without affecting YopBD secretion. These data are in disagreement with
the previous report that LcrV may be required for the secretion of YopB
and YopD (30).

View larger version (48K):
[in a new window]
Fig. 2.
LcrV is required for the low calcium
regulation of the lcrGVHyopBD operon. Y. enterocolitica strains W22703 (wild type (WT)) and CT1
(lcrV
) were transformed with pDA37 (vector
control), pVL49 (lcrV), or pVL47 (GST-lcrV) and
grown in the presence or absence of calcium for 3 h at 37 °C.
Cultures were centrifuged, and the supernatant (S) was
separated from the cell pellet (P). Protein in each sample
was precipitated with trichloroacetic acid, solubilized in sample
buffer, and analyzed by SDS-PAGE and immunoblotting. See Table II for
quantification of the data. CAT, chloramphenicol
acetyltransferase.
Expression of type III proteins in wild-type and mutant lcrV yersiniae
-D-galactopyranoside, Y. enterocolitica CT1 synthesized and secreted YopBDE at a
level similar to wild-type yersiniae (Fig. 2). GST-LcrV was not
secreted into the extracellular medium, indicating that fusion to
glutathione S-transferase indeed blocked transport of LcrV
by the type III machinery (Fig. 2). Expression of GST-LcrV abolished
the calcium repression of lcrGVHyopBD and caused Y. enterocolitica CT1/pVL47 to secrete large amounts of Yop proteins
even in the presence of calcium (Table II). Thus, a block in the
secretion of LcrV appears to induce the expression of
lcrGVHyopBD and to activate the type III pathway.

View larger version (76K):
[in a new window]
Fig. 3.
GST-LcrV binds to LcrG. A,
Y. enterocolitica CT1 was transformed with pVL47 (GST-LcrV)
and grown in tryptic soy broth at 37 °C. GST-LcrV was expressed by
inducing the tac promoter with 1 mM
isopropyl-1-thio-
-D-galactopyranoside. Cells were
disrupted in a French pressure cell. Extracts were centrifuged to
remove insoluble material, and the cleared lysate (L) was
subjected to affinity chromatography on glutathione resin. Column
flow-through (FT), wash (W), and eluate
(E) were collected and analyzed by Coomassie Blue-stained
SDS-PAGE. Arrowheads mark the migration of GST-LcrV
(black) and LcrG (white). The positions of
molecular mass markers (in kilodaltons) are indicated. B,
the eluate and load (L) samples were analyzed by
immunoblotting. To quantify binding of GST-LcrV to LcrG, we determined
the relative concentration of protein in the eluate and load by
scanning of immunoreactive signals. A eluate/load protein concentration
ratio of >1 reveals enrichment of proteins during the purification.
GST-LcrV copurified with LcrG, but not with LcrH, YopB, YopD, or
chloramphenicol acetyltransferase (CAT).
). Wild-type
yersiniae targeted YopEHMN into the cytosol of HeLa cells (Fig.
4). YopBDR and small amounts of LcrV were
secreted into the extracellular medium. Most of LcrV as well as YopQ
remained with the bacterial sediment after digitonin extraction of HeLa cells (Fig. 4). The lcrV mutant strain expressed very little
YopBDEHMN, LcrGH, and SycE (Fig. 5).
Moreover, lcrV mutant yersiniae failed to inject YopEHMN
into the cytosol of HeLa cells (Fig. 5). Instead, small amounts of
YopEHMN were secreted into the extracellular medium. Transformation of
Yersinia CT1 with plasmid pVL49 (encoding wild-type
lcrV) increased the expression of the yop virulon
and the targeting of YopEHMN to wild-type levels (Fig. 5).

View larger version (53K):
[in a new window]
Fig. 4.
Overexpression of LcrV and GST-LcrV in
wild-type yersiniae causes an up-regulation of the type III pathway.
Y. enterocolitica W22703 was transformed with pDA37 (vector
control), pVL49 (LcrV), or pVL47 (GST-LcrV). HeLa cells were infected
with yersiniae and subjected to digitonin (Dig)
fractionation and immunoblotting as described in the legend to Fig. 1.
Yersiniae overexpressing LcrV or GST-LcrV displayed an up-regulation of
the type III pathway as observed for the increased expression of
YopBDEHMNR. Med, tissue culture medium; S,
supernatant; P, pellet; FPT, farnesyl protein
transferase, acytosolic control for the permeabilization of HeLa
cells.

View larger version (57K):
[in a new window]
Fig. 5.
lcrV mutant yersiniae fail
to inject YopEHMN into HeLa cells. Y. enterocolitica
CT1 (lcrV
) was transformed with pDA37 (vector
control), pVL49 (LcrV), or pVL47 (GST-LcrV). HeLa cells were infected
with yersiniae and subjected to digitonin (Dig)
fractionation and immunoblotting as described in the legend to Fig. 1.
The lcrV mutant strain CT1 failed to target YopEHMN into
HeLa cells (Not (no type III targeting)
phenotype). Moreover, the expression of Yop proteins was reduced
compared with the wild-type parent strain (see Fig. 4). Expression of
plasmid-encoded LcrV in the lcrV mutant strain CT1
restored type III targeting to wild-type levels. Furthermore,
expression of the non-secretable GST-LcrV in the lcrV mutant
strain CT1 not only restored type III targeting, but also caused
massive secretion of YopEHMN into the extracellular medium (Los
phenotype). Med, tissue culture medium; S,
supernatant; P, pellet; FPT, farnesyl protein
transfer.

View larger version (128K):
[in a new window]
Fig. 6.
Immunofluorescence microscopy of HeLa cells
infected with Y. enterocolitica strains.
Samples were fixed with formaldehyde and stained with anti-YopE
antibodies, followed by fluorescein isothiocyanate-conjugated
anti-rabbit IgG antibody. Fluorescence and dark-field emission images
were captured in an Olympus microscope using a Hamamatsu CCD camera and
fused. The YopE signal is indicated in green. YopE was
detected in the cytosol of HeLa cells infected with Y. enterocolitica strains W22703/pDA37 (A), CT1/pVL49
(C), and CT1/pVL47 (D). The YopE signal was
reduced in HeLa cells infected with the lcrV mutant strain
CT1/pDA37 (B). Each experiment was performed using identical
light and fluorescence intensity conditions. No attempt was made to
optimize the selection of microscopic fields or staining
patterns.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and interferon-
production (55), in addition to
preventing the chemotaxis of neutrophils (36). Thus, it is conceivable
that anti-LcrV antibodies may neutralize the immunosuppressive effects
of secreted LcrV molecules rather than interfere with the type III
targeting mechanism (38).
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Supported by a fellowship from the National Science Foundation.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Persson, C.,
Carballeira, N.,
Wolf-Watz, H.,
and Fallman, M.
(1997)
EMBO J.
16,
2307-2318
2.
Cornelis, G. R.,
Boland, A.,
Boyd, A. P.,
Geuijen, C.,
Iriarte, M.,
Neyt, C.,
Sory, M.-P.,
and Stainier, I.
(1998)
Microbiol. Mol. Biol. Rev.
62,
1315-1352
3.
Cornelis, G.,
Sluiters, C.,
de Rouvroit, C. L.,
and Michiels, T.
(1989)
J. Bacteriol.
171,
254-262
4.
Wattiau, P.,
and Cornelis, G. R.
(1994)
J. Bacteriol.
176,
3878-3884
5.
Goguen, J. D.,
Yother, J.,
and Straley, S. C.
(1984)
J. Bacteriol.
160,
842-848
6.
Straley, S. C.,
Plano, G. V.,
Skrzypek, E.,
Haddix, P. L.,
and Fields, K. A.
(1993)
Mol. Microbiol.
8,
1005-1010
7.
Cornelis, G. R.,
and Wolf-Watz, H.
(1997)
Mol. Microbiol.
23,
861-867
8.
Lee, V. T.,
Anderson, D. M.,
and Schneewind, O.
(1998)
Mol. Microbiol.
28,
593-601
9.
Lee, V. T.,
and Schneewind, O.
(1999)
Mol. Microbiol.
31,
1619-1629
10.
Lee, V. T.,
and Schneewind, O.
(1999)
Immunol. Rev.
168,
241-255
11.
Rosqvist, R.,
Magnusson, K.-E.,
and Wolf-Watz, H.
(1994)
EMBO J.
13,
964-972
12.
Hakansson, S.,
Gaylov, E.,
Rosqvist, R.,
and Wolf-Watz, H.
(1996)
Mol. Microbiol.
20,
593-603
13.
Persson, C.,
Nordfelth, R.,
Holmstrom, A.,
Hakansson, S.,
Rosqvist, R.,
and Wolf-Watz, H.
(1995)
Mol. Microbiol.
18,
135-150
14.
Boland, A.,
Sory, M.-P.,
Iriarte, M.,
Kerbourch, C.,
Wattiau, P.,
and Cornelis, G. R.
(1996)
EMBO J.
15,
5191-5201
15.
Iriarte, M.,
and Cornelis, G. R.
(1998)
Mol. Microbiol.
29,
915-929
16.
Mills, S. D.,
Boland, A.,
Sory, M.-P.,
van der Smissen, P.,
Kerbouch, C.,
Finlay, B. B.,
and Cornelis, G. R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12638-12643
17.
Petterson, J.,
Nordfelth, R.,
Dubinina, E.,
Bergman, T.,
Gustafsson, M.,
Magnusson, K.-E.,
and Wolf-Watz, H.
(1996)
Science
273,
1231-1233
18.
Galyov, E. E.,
Hakansson, S.,
Forsberg, A.,
and Wolf-Watz, H.
(1993)
Nature
361,
730-732
19.
Rosqvist, R.,
Bolin, I.,
and Wolf-Watz, H.
(1988)
Infect. Immun.
56,
2139-2143
20.
Rosqvist, R.,
Forsberg, A.,
Rimpilainen, M.,
Bergman, T.,
and Wolf-Watz, H.
(1990)
Mol. Microbiol.
4,
657-667
21.
Rosqvist, R.,
Forsberg, A.,
and Wolf-Watz, H.
(1991)
Infect. Immun.
59,
4562-4569
22.
Yother, J.,
Chamness, T. W.,
and Goguen, J. D.
(1986)
J. Bacteriol.
165,
443-447
23.
Michiels, T.,
Wattiau, P.,
Brasseur, R.,
Ruysschaert, J.-M.,
and Cornelis, G.
(1990)
Infect. Immun.
58,
2840-2849
24.
Stainier, I.,
Iriarte, M.,
and Cornelis, G. R.
(1997)
Mol. Microbiol.
26,
833-843
25.
Rimpilainen, M.,
Forsberg, A.,
and Wolf-Watz, H.
(1992)
J. Bacteriol.
174,
3355-3363
26.
Michiels, T.,
Vanooteghem, J.-C.,
Lambert de Rouvroit, C.,
China, B.,
Gustin, A.,
Boudry, P.,
and Cornelis, G. R.
(1991)
J. Bacteriol.
173,
4994-5009
27.
Bergmann, T.,
Erickson, K.,
Galyov, E.,
Persson, C.,
and Wolf-Watz, H.
(1994)
J. Bacteriol.
176,
2619-2626
28.
Allaoui, A.,
Woestyn, S.,
Sluiters, C.,
and Cornelis, G.
(1994)
J. Bacteriol.
176,
4534-4542
29.
Allaoui, A.,
Schulte, R.,
and Cornelis, G. R.
(1995)
Mol. Microbiol.
18,
343-355
30.
Sarker, M. R.,
Neyt, C.,
Stainier, I.,
and Cornelis, G. R.
(1998)
J. Bacteriol.
180,
1207-1214
31.
Nilles, M. L.,
Fields, K. A.,
and Straley, S. C.
(1998)
J. Bacteriol.
180,
3410-3420
32.
Skrzypek, E.,
and Straley, S. C.
(1993)
J. Bacteriol.
175,
3520-3528
33.
Boyd, A. P.,
Sory, M.-P.,
Iriarte, M. I.,
and Cornelis, G. R.
(1998)
Mol. Microbiol.
27,
425-436
34.
Sarker, M. R.,
Sory, M.-P.,
Boyd, A. P.,
Iriarte, M. I.,
and Cornelis, G. R.
(1998)
Infect. Immun.
66,
2976-2979
35.
Nilles, M. L.,
Williams, A. W.,
Skrzypek, E.,
and Straley, S. C.
(1997)
J. Bacteriol.
179,
1307-1316
36.
Welkos, S.,
Friedlander, A.,
McDowel, D.,
Weeks, J.,
and Tobery, S.
(1998)
Microb. Pathog.
24,
185-196
37.
Petterson, J.,
Holmstrom, A.,
Hill, J.,
Frithz-Lindsten, E.,
von Euler-Matell, A.,
Carlsson, E.,
Titball, R.,
Forsberg, A.,
and Wolf-Watz, H.
(1999)
Mol. Microbiol.
32,
961-976
38.
Fields, K. A.,
Nilles, M. L.,
Cowan, C.,
and Straley, S. C.
(1999)
Infect. Immun.
67,
5395-5408
39.
Cornelis, G. R.
(1998)
J. Bacteriol.
180,
5495-5504
40.
Cornelis, G. R.,
and Colson, C.
(1975)
J. Gen. Microbiol.
87,
285-291
41.
Cheng, L. W.,
Anderson, D. M.,
and Schneewind, O.
(1997)
Mol. Microbiol.
24,
757-765
42.
Price, S. B.,
Leung, K. Y.,
Barve, S. S.,
and Straley, S. C.
(1989)
J. Bacteriol.
171,
5646-5653
43.
Bergmann, T.,
Hakansson, S.,
Forsberg, A.,
Norlander, L.,
Macellaro, A.,
Backman, A.,
Bolin, I.,
and Wolf-Watz, H.
(1991)
J. Bacteriol.
173,
1607-1616
44.
Anderson, D. M.,
and Schneewind, O.
(1999)
Mol. Microbiol.
31,
1139-1148
45.
Black, D. S.,
and Bliska, J. B.
(1997)
EMBO J.
16,
2730-2744
46.
Reiss, B.,
Sprengel, R.,
and Schaller, H.
(1984)
EMBO J.
3,
3317-3322
47.
Hoe, N. P.,
and Goguen, J. D.
(1993)
J. Bacteriol.
175,
7901-7909
48.
Hoe, N. P.,
Minion, F. C.,
and Goguen, J. D.
(1992)
J. Bacteriol.
174,
4275-4286
49.
Michiels, T.,
and Cornelis, G. R.
(1991)
J. Bacteriol.
173,
1677-1685
50.
Williams, A. W.,
and Straley, S. C.
(1998)
J. Bacteriol.
180,
350-358
51.
Burrows, T. W.,
and Bacon, G. A.
(1956)
Br. J. Exp. Pathol.
37,
481-493
52.
Burrows, T. W.,
and Bacon, G. A.
(1958)
Br. J. Exp. Pathol.
39,
278-291
53.
Une, T.,
and Brubaker, R. R.
(1984)
J. Immunol.
133,
2226-2230
54.
Hill, J.,
Leary, S. E. C.,
Griffin, K.,
Williamson, E. D.,
and Titball, R. W.
(1997)
Infect. Immun.
65,
4476-4482
55.
Nakajima, R.,
Motin, V. L.,
and Brubaker, R. R.
(1995)
Infect. Immun.
63,
3021-3029
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
K. E. Riordan, J. A. Sorg, B. J. Berube, and O. Schneewind Impassable YscP Substrates and Their Impact on the Yersinia enterocolitica Type III Secretion Pathway J. Bacteriol., September 15, 2008; 190(18): 6204 - 6216. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Caroline, F. Eric, Y.-S. T. Bohn, E. Sylvie, and I. Attree Oligomerization of PcrV and LcrV, Protective Antigens of Pseudomonas aeruginosa and Yersinia pestis J. Biol. Chem., August 29, 2008; 283(35): 23940 - 23949. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Broms, M. S. Francis, and A. Forsberg Diminished LcrV Secretion Attenuates Yersinia pseudotuberculosis Virulence J. Bacteriol., December 1, 2007; 189(23): 8417 - 8429. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Urbanowski, E. D. Brutinel, and T. L. Yahr Translocation of ExsE into Chinese Hamster Ovary Cells Is Required for Transcriptional Induction of the Pseudomonas aeruginosa Type III Secretion System Infect. Immun., September 1, 2007; 75(9): 4432 - 4439. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Davis and J. Mecsas Mutations in the Yersinia pseudotuberculosis Type III Secretion System Needle Protein, YscF, That Specifically Abrogate Effector Translocation into Host Cells J. Bacteriol., January 1, 2007; 189(1): 83 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Sorg, B. Blaylock, and O. Schneewind Secretion signal recognition by YscN, the Yersinia type III secretion ATPase PNAS, October 31, 2006; 103(44): 16490 - 16495. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. DeBord, D. M. Anderson, M. M. Marketon, K. A. Overheim, R. W. DePaolo, N. A. Ciletti, B. Jabri, and O. Schneewind Immunogenicity and Protective Immunity against Bubonic Plague and Pneumonic Plague by Immunization of Mice with the Recombinant V10 Antigen, a Variant of LcrV. Infect. Immun., August 1, 2006; 74(8): 4910 - 4914. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Sorg, N. C. Miller, M. M. Marketon, and O. Schneewind Rejection of Impassable Substrates by Yersinia Type III Secretion Machines J. Bacteriol., October 15, 2005; 187(20): 7090 - 7102. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Marketon, R. W. DePaolo, K. L. DeBord, B. Jabri, and O. Schneewind Plague Bacteria Target Immune Cells During Infection Science, September 9, 2005; 309(5741): 1739 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Overheim, R. W. DePaolo, K. L. DeBord, E. M. Morrin, D. M. Anderson, N. M. Green, R. R. Brubaker, B. Jabri, and O. Schneewind LcrV Plague Vaccine with Altered Immunomodulatory Properties Infect. Immun., August 1, 2005; 73(8): 5152 - 5159. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Ryndak, H. Chung, E. London, and J. B. Bliska Role of Predicted Transmembrane Domains for Type III Translocation, Pore Formation, and Signaling by the Yersinia pseudotuberculosis YopB Protein Infect. Immun., April 1, 2005; 73(4): 2433 - 2443. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Goure, A. Pastor, E. Faudry, J. Chabert, A. Dessen, and I. Attree The V Antigen of Pseudomonas aeruginosa Is Required for Assembly of the Functional PopB/PopD Translocation Pore in Host Cell Membranes Infect. Immun., August 1, 2004; 72(8): 4741 - 4750. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Cambronne, J. A. Sorg, and O. Schnee |